TRCT
KYTX icon

Tower Research Capital (TRC)’s Kyverna Therapeutics KYTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27K Sell
3,128
-1,945
-38% -$16.2K ﹤0.01% 3265
2025
Q4 		$47.7K Sell
5,073
-1,158
-19% -$8.6K ﹤0.01% 2454
2025
Q3 		$37.4K Sell
6,231
-4,675
-43% -$18.7K ﹤0.01% 2751
2025
Q2 		$33.5K Buy
10,906
+2,733
+33% +$6.76K ﹤0.01% 3319
2025
Q1 		$15.8K Buy
8,173
+5,431
+198% +$16K ﹤0.01% 3205
2024
Q4 		$10.3K Sell
2,742
-10,107
-79% -$48.4K ﹤0.01% 3819
2024
Q3 		$62.8K Buy
+12,849
New +$99.1K ﹤0.01% 2586
2024
Q2 		– Sell
-766
Closed -$19K – 6057
2024
Q1 		$19K Buy
+766
New +$21.4K ﹤0.01% 3047

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Tower Research Capital (TRC)'s KYTX Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Kyverna Therapeutics (KYTX) stake by 38% in Q1 2026, selling an estimated $16.2K and leaving 3,128 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #3265.

Tower Research Capital (TRC) first reported a position in KYTX in Q1 2024 and has held it in 8 quarters since. The position peaked at $62.8K in Q3 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Tower Research Capital (TRC) held 3,128 shares of Kyverna Therapeutics worth $27K as of Q1 2026.
  • Tower Research Capital (TRC) sold 1,945 Kyverna Therapeutics shares in Q1 2026, an estimated $16.2K.
  • Kyverna Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3265 holding.
  • Tower Research Capital (TRC) first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • Tower Research Capital (TRC)'s Kyverna Therapeutics position peaked at $62.8K in Q3 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.